Aptar appoints Gael Touya CEO effective Sept 1, 2026; Stephan Tanda to retire end-2026
- Gael Touya becomes CEO and is appointed to the Board on Sept 1, 2026; Stephan Tanda will advise through year-end 2026 and retire from the Board by end-2026.
- Aptar Pharma delivered ~82% topline growth since 2018 and expanded nasal/respiratory delivery into systemic applications including biologics.
- From year-end 2017 to year-end 2025 adjusted EBITDA margins rose from ~19% to ~22%, adjusted EPS grew 67%, and capital returned to shareholders increased ~100%.
- Aptar completed roughly 20 bolt-on acquisitions (majority in Pharma), including the 2018 acquisition of Active Material Science.
Leadership change
Gael Touya will become President and CEO of AptarGroup on September 1, 2026; the Board will appoint him as a director that day. Stephan B. Tanda will remain as an advisor through the end of 2026 and retire from the Board by year‑end 2026.
Touya background
Touya has 30+ years at Aptar with roles across Europe, Asia and North America, including President of Aptar Pharma since 2018, President of Food + Beverage (now Aptar Closures), President Food + Beverage Europe, Vice President of Business Development for Skincare & Color Cosmetics, and P&L leadership in China and Japan; he holds a business degree from Excelia, an MBA from ESSEC and completed the Harvard Business School Advanced Management Program.
Pharma performance and strategy
Since 2018 Aptar Pharma delivered approximately 82% topline growth; the segment expanded its technologies and services to support development through commercialization, combined targeted acquisitions with organic development, added regulatory and clinical development capabilities, patient onboarding and digital health, and extended nasal/respiratory delivery into systemic applications and biologics.
Tanda tenure and financials
Since 2017 Aptar completed roughly 20 bolt‑on acquisitions (majority in Pharma), including Active Material Science in 2018; adjusted EBITDA margins rose from ~19% at year‑end 2017 to ~22% at year‑end 2025, adjusted EPS increased 67%, capital returned to shareholders grew ~100%, and Aptar recorded its 32nd consecutive annual dividend increase in 2025.
Source: Aptar